drug_type
RELEVANT_DRUG
intervention_type
Antibody-drug conjugate (ADC)
drug_description
An antibody–drug conjugate combining trastuzumab (humanized anti-HER2 IgG1) with the maytansinoid DM1 payload; binds HER2/ERBB2 to inhibit signaling, promote receptor internalization, and mediate ADCC, while the DM1 component disrupts microtubules leading to mitotic arrest and apoptosis.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Ado-Trastuzumab Emtansine
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
Humanized anti-HER2 IgG1 (trastuzumab) targets HER2/ERBB2, inhibiting HER2 signaling, promoting receptor internalization, and mediating ADCC. The conjugated maytansinoid payload (DM1) is internalized and released to disrupt microtubules, causing mitotic arrest and apoptosis in HER2-overexpressing tumor cells.
drug_name
Trastuzumab emtansine (T-DM1)
nct_id_drug_ref
NCT06125834